Clinical Trial

Population-based Atrial Fibrillation Screening in Individuals With NT-proBNP Above Median in the Tromsø Study

Study acronym: PAFS-Tromsø
Recruiting
View on ClinicalTrials.gov →
Summary
The aim is to investigate whether screening with long-term ECG monitoring in individuals with elevated NT-proBNP leads to a lower incidence of ischeamic stroke and death from vascular causes. The project is a sub-study within the 8th wave of the population based Tromsø Study. Information on previous diseases, medication use, and risk factors is collected through questionnaires, blood samples, and measurements of height, weight, blood pressure, and ECG. A total of 4,000 individuals with NT-proBNP levels above the median, without previously known atrial fibrillation (AF) or ongoing anticoagulation therapy, will be randomized to either long-term heart rhythm monitoring (7 days) or a control group without long-term ECG monitoring (2,000 in each group). Individuals with AF in the intervention group will be offered anticoagulation therapy in accordance with current guidelines. The intervention group and the control group will be compared with regards to incident stroke and death within a 6-year follow-up period. Information on endpoints and anticoagulation use will be obtained through linkage to national registries.
Trial Details
NCT Number NCT07343895
Lead Sponsor University Hospital of North Norway
Collaborators: UiT The Arctic University of Norway
Conditions Atrial Fibrillation (AF), Stroke, NT-pro-BNP, Cognitive Function and Well-Being, Heart Failure
Enrollment 4,000 participants
Start Date 2025-10-24
Primary Completion 2032-03-01 (estimated)
Study Completion 2035-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-15